Cabio Biotech: Chinese Infant Formula Recalled Over Safety Concerns

Concerns have emerged after the withdrawal of infant formula from the market, with attention now turning to Cabio Biotech, a Chinese company under suspicion. Authorities are investigating the potential risks associated with the firm's products for young children.

A Surge in Infant Formula Recalls Raises Global Alarm

A wave of recalls affecting infant milk formula has rattled more than sixty countries since December, sending shockwaves through the baby food industry. At the heart of this international concern lies a suspected contamination with cereulide, a bacterial toxin known to cause acute vomiting. The situation escalated further when French authorities initiated investigations following the deaths of two infants who had consumed a recalled product in early January, originally produced by Nestlé. To date, however, officials emphasize that no definitive link has been established between these tragic fatalities and the contaminated formula.

The Cabio Biotech Connection: Supplier Under Scrutiny

Amid mounting questions, attention has turned to one Chinese company: Cabio Biotech, based in Wuhan. This major supplier is believed to provide numerous manufacturers—including industry giants like Nestlé and Danone—with oil rich in arachidonic acid (ARA), a nutrient essential for brain development. Multiple sources familiar with the ongoing investigation have identified this ingredient as the likely source of the cereulide detected in affected batches.

While most companies have declined to publicly confirm their suppliers, French producer Nutribio has openly named Cabio Biotech as their provider. Advocacy group Foodwatch also notes that Cabio is among the world’s few large-scale producers of ARA—a detail corroborated by the company’s own financial disclosures. Meanwhile, France’s Ministry of Agriculture has observed that all recent recalls seem to trace back to this same Chinese source.

A Shadow Cast by Previous Scandals

This latest incident inevitably brings back memories of the notorious 2008 Chinese melamine crisis, which claimed six infant lives and left some 300,000 babies ill. Efforts to rebuild public trust in the sector have been ongoing ever since—a task now complicated by fresh doubts.

Publicly, both Cabio Biotech and Chinese authorities have maintained an air of reserve. Despite repeated media requests, Cabio has remained silent. Officially, Beijing issued only a brief mid-January statement pledging strong oversight and emphasizing its commitment to ensuring “the quality and safety” of infant formula—without naming any specific company involved.

Cabio Biotech: Market Power and International Repercussions

Founded in Wuhan in 2004, Cabio Biotech commands more than half the domestic market for arachidonic acid and supplies other key nutrients such as DHA and beta-carotene for both children and adults. The company’s international profile has left it exposed: its share price tumbled sharply on China’s stock exchange at the height of January’s European-driven recalls. Several factors explain this market response:

• The prominence of its client list—including top multinationals;
• The centrality of ARA for infant nutrition;
• The impact on trust within global supply chains.

As investigations continue across continents, questions remain about quality control and transparency in a sector where mistakes can have devastating consequences for families worldwide.